Absci vs Maxcyte
Absci (ABSI) and Maxcyte (MXCT) side by side: how big they are, what they earn, how their shares have moved and what insiders, members of Congress and funds reported. Figures from filings and closing prices; none of this is a view on either stock.
- Market value
- $1.3B
- Last close
- $7.51
- 12 months
- +171.1%
- Market value
- $141M
- Last close
- $1.37
- 12 months
- −15.9%
At a glance
- The biggest part of Maxcyte's revenue is Product sales, 57% of the total in its last annual report.
- By market value, Absci ($1.3B) is about 9.2 times Maxcyte ($141M).
- Over the last 12 months Absci's share price moved +171.1% and Maxcyte's −15.9%; against the S&P 500 that is +165.4 points and −21.7 points.
- In their last fiscal years Absci kept -4113.7% of revenue as net income and Maxcyte -135.1%.
- In the last 90 days insiders reported 0 open-market purchases at Absci and 1 at Maxcyte; members of Congress disclosed 0 trades in Absci and 0 in Maxcyte.
- Next results: Absci Mar 22, 2027, Maxcyte Mar 12, 2027.
How each one makes money: Maxcyte revenue
Share prices on one chart
Absci and Maxcyte, and up to three more you add, drawn on the same scale so you can see which moved more.
Face to face
The figures that separate the two, drawn to the same scale. Every figure is also in the table below.
Size
Market value
Revenue, last fiscal year
Net income, last fiscal year
Every figure
| Absci ABSINASDAQ · Services-Commercial Physical & Biological Research | Maxcyte MXCTNASDAQ · Services-Commercial Physical & Biological Research | |
|---|---|---|
| Size and profitability | ||
| Market value | $1.3B | $141M |
| Revenue, last fiscal year | $2.8M | $33M |
| Net income, last fiscal year | −$115M | −$44.6M |
| Net marginNet income as a share of revenue | -4113.7% | -135.1% |
| Free cash flow | ||
Prices are end-of-day closes, and fundamentals are the companies' last annual figures from their SEC filings: a − or + in the table is a fact of the filing or the close, not a forecast. Market value is the company-level figure at the last close. Counts are of records OQRO holds, by their date; insider history since 2006 comes from the SEC's insider transactions data sets and every filing since. Planned sales under a 10b5-1 plan are counted like other sales.
Common questions
How is Absci different from Maxcyte?
Absci (ABSI) is in Services-Commercial Physical & Biological Research on NASDAQ, with $2.8M of revenue in its last fiscal year and a net margin of -4113.7%. Maxcyte (MXCT) is in Services-Commercial Physical & Biological Research on NASDAQ, with $33M of revenue in its last fiscal year and a net margin of -135.1%. The biggest part of Maxcyte's revenue is Product sales, 57% of the total in its last annual report. The table above sets their figures side by side; it compares filings and is not a view on either stock.
How do Absci and Maxcyte compare in size?
Absci has the larger market value: Absci $1.3B and Maxcyte $141M, at the last close.
Whose share price rose more over the last 12 months, ABSI or MXCT?
Over the last 12 months Absci moved +171.1% and Maxcyte −15.9%. Past price moves say nothing about the future.
Which has had more insider buying, Absci or Maxcyte?
Since 2006, Absci insiders reported 15 open-market purchases against 11 for Maxcyte. These are counts of what was filed, not a view on either stock.
Do members of Congress trade ABSI or MXCT?
In the last 12 months, members of Congress disclosed 0 trades in Absci (ABSI) and 0 in Maxcyte (MXCT).
When did insiders last buy ABSI and MXCT?
Absci: Sep 24, 2025. Maxcyte: Nov 18, 2026.
See the record behind any of these
A free account opens the full history of every insider and company since 2006, the screener, alerts, Congress trades and fund moves.
Absci pageMaxcyte pageRare insider trades this weekAll comparisons
https://oqro.io/compare/absi-vs-mxct

